Castle Biosciences (CSTL) Share-based Compensation (2018 - 2026)

Castle Biosciences has disclosed Share-based Compensation across 9 years of filings, most recently posting $9.8 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $9.8 million, down 12.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.5 million (down 8.88% YoY), and the FY2025 annual result was $45.9 million, down 8.8% from the prior year.
• Share-based Compensation came in at $9.8 million for Q1 2026 at Castle Biosciences, down from $11.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q1 2023 to a low of $8.4 million in Q1 2022.
• The 5-year median for Share-based Compensation is $11.4 million (2024), against an average of $11.4 million.
• Across the five-year window, Share-based Compensation surged 84.28% in 2022 and slipped 14.96% in 2025, its largest moves.
• Castle Biosciences' Share-based Compensation stood at $9.9 million in 2022, then increased by 18.94% to $11.8 million in 2023, then retreated by 3.08% to $11.4 million in 2024, then retreated by 0.29% to $11.4 million in 2025, then dropped by 14.29% to $9.8 million in 2026.
• The last three Share-based Compensation figures came in at $9.8 million (Q1 2026), $11.4 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.